Index > Vol. 85/2005 > Iss. 3/May > pp. 194-202 > Abstract
Letter to the Editor

Peroxisome Proliferator-activated Receptors and their Relevance to Dermatology

doi: 10.1080/00015550510030104

Abstract:

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily and are expressed in a variety of tissues including skin and cells of the immune system. They act as ligand-dependent transcription factors which heterodimerize with retinoid X receptors to allow binding to and activation of PPAR responsive genes. Through this mechanism, PPAR ligands can control a wide range of physiological processes. Based on their effects in vitro and in vivo PPAR agonists and antagonists have the potential to become important therapeutic agents for the treatment of various skin diseases. PPARs can also be activated directly by phosphorylation to have ligand-independent effects. This review will discuss the physiology of PPARs relating this to skin pathology and their role as a target for novel therapies, psoriasis, PPARs, wound healing, thiazolidinediones, transcription factors

Key words:

psoriasis, PPARs, wound healing, thiazolidinediones, transcription factors

References:

  1. Issemann, I, Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990; 347: 645–650
  2. Jones, D. C, Ding, X, Daynes, R. A. Nuclear receptor peroxisome proliferator−activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem, 2002; 277: 6838–6845
  3. Westergaard, M, Henningsen, J, Svendsen, M. L, Johansen, C, Jensen, U. B, Schroder, H. D. Modulation of keratinocyte gene expression and differentiation by PPAR−selective ligands and tetradecylthioacetic acid. J Invest Dermatol, 2001; 116, 702–712 et al.
  4. Westergaard, M, Henningsen, J, Johansen, C, Rasmussen, S, Svendsen, M. L, Jensen, U. B. Expression and localization of peroxisome proliferator−activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol, 2003; 121: 1104–1117 et al.
  5. Larsen, L. K, Amri, E. Z, Mandrup, S, Pacot, C, Kristiansen, K. Genomic organization of the mouse peroxisome proliferator−activated receptor beta/delta gene: alternative promoter usage and splicing yield transcripts exhibiting differential translational efficiency. Biochem J, 2002; 366: 767–775
  6. Michalik, L, Desvergne, B, Tan, N. S, Basu−Modak, S, Escher, P, Rieusset, J, Impaired skin wound healing in peroxisome proliferator−activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol, 2001; 154, 799–814 et al.
  7. Tan, N. S, Michalik, L, Desvergne, B, Wahli, W. Peroxisome proliferator−activated receptor (PPAR)−beta as a target for wound healing drugs: what is possible? Am J Clin Dermatol, 2003; 4: 523–530
  8. Elbrecht, A, Chen, Y, Cullinan, C, A, Hayes, N, Leibowitz, M, Moller, D. E. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun, 1996; 224, 431–437 et al.
  9. Greene, M. E, Blumberg, B, McBride, O, W, Yi, H. F, Kronquist, K, Kwan, K. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr, 1995; 4: 281–299 et al.
  10. Nencioni, A, Wesselborg, S, Brossart, P. Role of peroxisome proliferator−activated receptor gamma and its ligands in the control of immune responses. Crit Rev Immunol, 2003; 23: 1–13
  11. Chen, W, Yang, C. C, Sheu, H. M, Seltmann, H, Zouboulis, C. C. Expression of peroxisome proliferator−activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol, 2003; 121: 441–447
  12. Bhagavathula, N, Nerusu, K. C, Lal, A, Ellis, C. N, Chittiboyina, A, Avery, M. A. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol, 2004; 122: 130–139 et al.
  13. Mao−Qiang, M, Fowler, A. J, Schmuth, M, Lau, P, Chang, S, Brown, B. E. Peroxisome−proliferator−activated receptor (PPAR)−gamma activation stimulates keratinocyte differentiation. J Invest Dermatol, 2004; 123: 305–312 et al.
  14. Nencioni, A, Grunebach, F, Zobywlaski, A, Denzlinger, C, Brugger, W, Brossart, P, Dendritic cell immunogenicity is regulated by peroxisome proliferator−activated receptor gamma. J Immunol, 2002; 169: 1228–1235
  15. Harris, S. G, Phipps, R. P. The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis. Eur J Immunol, 2001; 31: 1098–1105
  16. Blanquart, C, Barbier, O, Fruchart, J. C, Staels, B, Glineur, C. Peroxisome proliferator−activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol, 2003; 85: 267–273
  17. Huang, Q, Alvares, K, Chu, R, Bradfield, C. A, Reddy, J. K. Association of peroxisome proliferator−activated receptor and Hsp72. J Biol Chem, 1994; 269: 8493–8497
  18. Sumanasekera, W. K, Tien, E. S, Davis, J. W, Turpey, R, Perdew, G. H, Vanden Heuvel, J. P. Heat shock protein−90 (Hsp90) acts as a repressor of peroxisome proliferator−activated receptor−alpha (PPARalpha) and PPARbeta activity. Biochemistry, 2003; 42: 10726–10735
  19. Chen, F, Wang, M, O'Connor, J. P, He, M, Tripathi, T, Harrison, L. E, Phosphorylation of PPARgamma via active ERK1/2 leads to its physical association with p65 and inhibition of NF−kappabeta. J Cell Biochem, 2003; 90: 732–744
  20. Verma, A. K. Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment. Cancer Res, 1987; 47: 5097–5101
  21. Grommes, C, Landreth, G. E, Heneka, M. T. Antineoplastic effects of peroxisome proliferator−activated receptor gamma agonists. Lancet Oncol, 2004; 5, 419–429
  22. Elstner, E, Muller, C, Koshizuka, K, Williamson, E. A, Park, D, Asou, H. Ligands for peroxisome proliferator−activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A, 1998; 95: 8806–8811 et al.
  23. Sarraf, P, Mueller, E, Jones, D, King, F. J, DeAngelo, D. J, Partridge, J. B, Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med, 1998; 4: 1046–1052 et al.
  24. Kulke, M. H, Demetri, G. D, Sharpless, N. E, Ryan, D. P, Shivdasani, R, Clark, J. S. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy−resistant metastatic colorectal cancer. Cancer J, 2002; 8: 395–399 et al.
  25. Burstein, H, J, Demetri, G. D, Mueller, E, Sarraf, P, Spiegelman, B. M, Winer, E. P, Use of the peroxisome proliferator−activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat, 2003; 79: 391–397
  26. Jetten, A. M. Multi−stage program of differentiation in human epidermal keratinocytes: regulation by retinoids. J Invest Dermatol, 1990; 95, 44S–46S
  27. Hanley, K, Komuves, L. G, Ng, D. C, Schoonjans, K, He, S. S, Lau, P. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem, 2000; 275, 11484–11491 et al.
  28. Komuves, L. G, Hanley, K, Lefebvre, A. M, Man, M. Q, Ng, D. C, Bikle, D. D. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol, 2000; 115: 353–360 et al.
  29. Komuves, L. G, Hanley, K, Man, M. Q, Elias, P. M, Williams, M. L, Feingold, K. R, Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol, 2000; 115: 361–367
  30. Schmuth, M, Haqq, C. M, Cairns, W. J, Holder, J. C, Dorsam, S, Chang, S. Peroxisome proliferator−activated receptor (PPAR)−beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol, 2004; 122: 971–983 et al.
  31. Peters, J. M, Lee, S. S, Li, W, Ward, J. M, Gavrilova, O, Everett, C. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator−activated receptor beta(delta). Mol Cell Biol, 2000; 20: 5119–5128 et al.
  32. Muga, S. J, Thuillier, P, Pavone, A, Rundhaug, J. E, Boeglin, W. E, Jisaka, M. 8S−lipoxygenase products activate peroxisome proliferator−activated receptor alpha and induce differentiation in murine keratinocytes. Cell Growth Differ, 2000; 11: 447–454 et al.
  33. Hanley, K, Jiang, Y, Crumrine, D, Bass, N. M, Appel, R, Elias, P. M. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest, 1997; 100: 705–712 et al.
  34. Rivier, M, Castiel, I, Safonova, I, Ailhaud, G, Michel, S. Peroxisome proliferator−activated receptor−alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol, 2000; 114: 681–687
  35. Tan, N. S, Michalik, L, Noy, N, Yasmin, R, Pacot, C, Heim, M. Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev, 2001; 15: 3263–3277 et al.
  36. Tan, N. S, Michalik, L, Di Poi, N, Desvergne, B, Wahli, W. Critical roles of the nuclear receptor PPARbeta (peroxisome−proliferator−activated receptor beta) in skin wound healing. Biochem Soc Trans, 2004; 32: 97–102
  37. Poynter, M. E, Daynes, R. A. Peroxisome proliferator−activated receptor alpha activation modulates cellular redox status, represses nuclear factor−kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem, 1998; 273: 32833–32841
  38. Sheu, M. Y, Fowler, A. J, Kao, J, Schmuth, M, Schoonjans, K, Auwerx, J, Topical peroxisome proliferator activated receptor−alpha activators reduce inflammation in irritant and allergic contact dermatitis models, J Invest Dermatol, 2002; 118: 94–101 et al.
  39. Kippenberger, S, Loitsch, S. M, Grundmann−Kollmann, M, Simon, S, Dang, T. A, Hardt−Weinelt, K. Activators of peroxisome proliferator−activated receptors protect human skin from ultraviolet−B−light−induced inflammation. J Invest Dermatol, 2001; 117: 1430–1436 et al.
  40. Marx, N, Kehrle, B, Kohlhammer, K, Grub, M, Koenig, W, Hombach, V. PPAR activators as antiinflammatory mediators in human T lymphocytes, implications for atherosclerosis and transplantation−associated arteriosclerosis. Circ Res, 2002; 90: 703–710 et al.
  41. Marx, N, Sukhova, G. K, Collins, T, Libby, P, Plutzky, J. PPARalpha activators inhibit cytokine−induced vascular cell adhesion molecule−1 expression in human endothelial cells. Circulation, 1999; 99: 3125–3131
  42. Pasceri, V, Wu, H. D, Willerson, J. T, Yeh, E. T, Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator−activated receptor−gamma activators. Circulation, 2000; 101: 235–238
  43. Delerive, P, Martin−Nizard, F, Chinetti, G, Trottein, F, Fruchart, J. C, Najib, J. Peroxisome proliferator−activated receptor activators inhibit thrombin−induced endothelin−1 production in human vascular endothelial cells by inhibiting the activator protein−1 signaling pathway. Circ Res, 1999; 85: 394–402 et al.
  44. Delerive, P, Gervois, P, Fruchart, J. C, Staels, B. Induction of IkappaBalpha expression as a mechanism contributing to the anti−inflammatory activities of peroxisome proliferator−activated receptor−alpha activators. J Biol Chem, 2000; 275: 36703–36707
  45. Delerive, P, Fruchart, J. C, Staels, B. Peroxisome proliferator−activated receptors in inflammation control, J Endocrinol, 2001; 169: 453–459
  46. Delerive, P, De Bosscher, K, Besnard, S, Vanden Berghe, W, Peters, J. M, Gonzalez, F, J. Peroxisome proliferator−activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross−talk with transcription factors NF−kappaB and AP−1. J Biol Chem, 1999; 274: 32048–32054 et al.
  47. Ricote, M, Li, A. C, Willson, T. M, Kelly, C. J, Glass, C. K. The peroxisome proliferator−activated receptor−gamma is a negative regulator of macrophage activation. Nature, 1998; 391: 79–82
  48. Calnek, D. S, Mazzella, L, Roser, S, Roman, J, Hart, C. M. Peroxisome proliferator−activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol, 2003; 23: 52–57
  49. Hattori, Y, Hattori, S, Kasai, K, Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells. Hypertension, 1999; 33: 943–948
  50. Jiang, C, Ting, A. T, Seed, B. PPAR−gamma agonists inhibit production of monocyte inflammatory cytokines. Nature, 1998; 391: 82–86
  51. Jozkowicz, A, Dulak, J, Piatkowska, E, Placha, W, Dembinska−Kiec, A. Ligands of peroxisome proliferator−activated receptor−gamma increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages. Acta Biochim Pol, 2000; 47: 1147–1157
  52. Chawla, A, Barak, Y, Nagy, L, Liao, D, Tontonoz, P, Evans, R. M. PPAR−gamma dependent and independent effects on macrophage−gene expression in lipid metabolism and inflammation. Nat Med, 2001; 7: 48–52
  53. Li, M, Pascual, G, Glass, C. K. Peroxisome proliferator−activated receptor gamma−dependent repression of the inducible nitric oxide synthase gene, Mol Cell Biol, 2000; 20: 4699–4707
  54. Yang, X. Y, Wang, L. H, Chen, T, Hodge, D. R, Resau, J. H, DaSilva, L. Activation of human T lymphocytes is inhibited by peroxisome proliferator−activated receptor gamma (PPARgamma) agonists. PPARgamma co−association with transcription factor NFAT. J Biol Chem, 2000; 275: 4541–4544 et al.
  55. Yamakawa, K, Hosoi, M, Koyama, H, Tanaka, S, Fukumoto, S, Morii, H. Peroxisome proliferator−activated receptor−gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun, 2000; 271: 571–574 et al.
  56. Xin, X, Yang, S, Kowalski, J, Gerritsen, M. E. Peroxisome proliferator−activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem, 1999; 274: 9116–9121
  57. Pershadsingh, H. A, Sproul, J. A, Benjamin, E, Finnegan, J, Amin, N. M. Treatment of psoriasis with troglitazone therapy. Arch Dermatol, 1998; 134, 1304–1305
  58. Ellis, C. N, Varani, J, Fisher, G. J, Zeigler, M. E, Pershadsingh, H. A, Benson, S. C. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator−activated receptor−gamma inhibit keratinocyte proliferation. Arch Dermatol, 2000; 136: 609–616 et al.
  59. Robertshaw, H, Friedmann, P. S. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol, 2005; 15: 189–91
  60. Kuenzli, S, Saurat, J. H. Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. a pilot study. Dermatology, 2003; 206, 252–256
  61. Mossner, R, Kaiser, R, Matern, P, Kruger, U, Westphal, G. A, Brockmoller, J. Variations in the genes encoding the peroxisome proliferator−activated receptors alpha and gamma in psoriasis. Arch Dermatol Res, 2004; 296: 1–5 et al.
"